King's College Hospital NHS Trust

kch.nhs.uk

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

165

Active

36

Phase 3

11

Total enrollment

174,650

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Carvedilol2
Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 121
subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls1
Intravitreal 20% sulfahexafluoride (SF6) gas tamponade1
Colchicine 0.5 MG1
Blood and nasal swab sampling1
Dapagliflozin1
Empirical Hydrocortisone Protocol1
Targeted Treatment Protocol1
Angiotensin II1
Vasopressin1
Norepinephrine1

Next readouts

  • 2025-04-08
  • 2025-10-05
  • 2026-01
  • 2026-12
  • 2027-12-31
  • 2028-09
  • 2028-12

Top conditions

  • Leukemia, Myeloid, Acute5
  • Chronic Kidney Diseases5
  • Obesity5
  • Myelodysplastic Syndromes5
  • Cardiovascular Diseases4
  • Diverticular Disease4
  • Dyspnea4
  • Miscarriage in First Trimester3

Frequently asked questions about King's College Hospital NHS Trust

How many clinical trials does King's College Hospital NHS Trust have on ClinicalTrials.gov?
King's College Hospital NHS Trust is listed as the lead sponsor on 165 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
How many of King's College Hospital NHS Trust's trials are in Phase 3?
11 of King's College Hospital NHS Trust's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does King's College Hospital NHS Trust focus on?
King's College Hospital NHS Trust's most-studied conditions on ClinicalTrials.gov are Leukemia, Myeloid, Acute, Chronic Kidney Diseases, Obesity, Myelodysplastic Syndromes, Cardiovascular Diseases.
When are King's College Hospital NHS Trust's next clinical trial readouts?
King's College Hospital NHS Trust has 7 upcoming primary-completion readouts tracked here; the soonest is “Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue)”, expected around 2025-04-08.